BenevolentAI, an AI Pharmaceutical Company, Announces Further Workforce Reduction and Closure of US Office

BenevolentAI, a publicly listed AI pharmaceutical company based in the UK, has recently made the decision to implement another round of layoffs, reducing its workforce by 30%. In addition, the company has announced the closure of its office in the United States. This strategic move comes as a result of challenges faced by the company in its clinical trials and a shift in focus towards its drug development pipeline.

BenevolentAI had previously experienced setbacks in its clinical trials for BEN-2293, a topical pan-Trk inhibitor used in the treatment of atopic dermatitis. The drug failed to achieve the secondary efficacy endpoints of reducing itchiness and inflammation in patients. As BEN-2293 was the company's fastest-progressing pipeline and the only clinical candidate, this clinical failure had a significant impact on BenevolentAI. In response, the company initiated a major restructuring, leading to the layoff of nearly 180 employees, representing approximately 50% of its workforce.

Following the previous round of layoffs, BenevolentAI underwent a restructuring process, focusing on two core business divisions: the artificial intelligence software products group and the drug development department. However, the company has recently made further adjustments to its strategy. Despite initial development and user testing, the software development department did not proceed with full commercialization due to the substantial investment required and the time needed to achieve meaningful financial returns. Instead, BenevolentAI decided to allocate resources to its drug discovery collaborations and internal pipeline.

With the latest round of layoffs, approximately 75 employees, out of a total of 248 at the end of last year, will be affected. The cost savings resulting from the workforce reduction will be directed towards the development of BEN-8744, a PDE10 inhibitor for ulcerative colitis. BenevolentAI is preparing to include this candidate drug in Phase 1b/2a clinical trials. The company estimates that these changes will reduce cash burn by approximately 20% and extend its cash runway until the end of the third quarter of 2025.

Despite these measures, investor dissatisfaction has impacted BenevolentAI's stock price, which has remained below 1 Euro for most of 2024, restricting the company's ability to raise funds. To bridge this gap, the biotechnology firm aims to secure one or more partnerships and obtain at least one licensed pipeline project during this year. BenevolentAI has existing collaborations with AstraZeneca, Eli Lilly, and Merck KGaA. The company plans to retain critical skills, expertise, and capabilities while supporting new and existing collaborations.

BenevolentAI, an AI pharmaceutical company, has announced a significant reduction in its workforce and the closure of its US office. The decision follows the challenges faced by the company in its clinical trials and a strategic shift towards its drug development pipeline. By focusing resources on drug discovery collaborations and key pipeline projects, BenevolentAI aims to optimize its financial position and advance promising candidates, such as BEN-8744 for ulcerative colitis. As the company navigates these changes, it seeks to establish partnerships and secure licensing agreements to drive future growth and innovation in the field of AI-driven pharmaceuticals.